Media Inquiries:
Mario Fante
Aviator PR
(617) 763-9887
mario@aviator-pr.com

font size:

 

 
 

Mar-20-2008   ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi®) Therapeutic
Aug-23-2007   ProNAi Therapeutics Announces First DNAi® Mechanism of Action Studies for PNT2258 Oncology Drug Candidate
Jun-14-2007   ProNAi Names Polymun as Preferred Manufacturer of PNT2258 DNAi®-based Cancer Therapeutic
Apr-17-2007   ProNAi Announces Preclinical Success for PNT2258 Therapeutic – Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin’s Lymphoma
Mar-05-2007   ProNAi and Novosom AG Announce Collaboration to Enable Delivery of DNAi®-based Cancer Therapeutics
Jan-08-2007   ProNAi Announces DNA Interference (DNAi®) Drug Development Strategy for 2007
Oct-24-2006   ProNAi Closes Successful Bridge Funding Round, Secures $6.65 Million Total
Oct-12-2006   ProNAi Announces New Scientific Advisory Board
Sep-26-2006   ProNAi Announces Executive Team Buildup, Names New CEO and Top Development Management
Sep-12-2006   ProNAi Wins $3.3 Million Funding from Michigan Economic Development Corporation
Oct-19-2005   ProNAi Therapeutics Raises $4.25m to Develop a New Class of Therapies That Target DNA